Editorial illustration for OpenAI's Miles Wang in Talks for USD 2B AI Drug Discovery Startup
OpenAI Researcher Launches $2B AI Drug Discovery Startup
Miles Wang is leaving OpenAI to start a company that applies AI models to drug discovery, according to four people familiar with his plans. Wang, whose research at OpenAI focused on using AI to speed up scientific and biological work, is reportedly in talks to raise roughly $200 million at a $2 billion valuation, with Lightspeed said to be discussing a lead position in the round. Several OpenAI researchers are expected to follow him to the new venture. Nothing is signed yet, and the numbers could shift before any deal closes.
Wang pushed back on the reported funding details and how the company was described, though he didn't offer alternative figures. Lightspeed hasn't responded to requests for comment.
The move lands amid a run of big checks for AI-driven drug discovery. Chai Discovery, co-founded by another OpenAI alum, Josh Meier, just raised $400 million at a $3.8 billion valuation. Google DeepMind's Isomorphic Labs closed a $2.1 billion Series B in May. Wang's startup may aim narrower: finding new applications for drugs that are already FDA-approved or that failed trials, a path that can shorten the road to revenue considerably.
Wang’s new startup may be working on AI models that will help find new uses for existing drugs and possibly those that previously failed in trials, a couple of sources told TechCrunch. Finding new uses for FDA-approved drugs can result in significantly faster time to revenue than developing new drugs from scratch, as these medicines have already been tested for safety.
Why this matters
Wang hasn't shipped a product or published results from this venture, yet he's already talking to Lightspeed about $200 million at a $2 billion valuation. That's the OpenAI premium at work: a researcher's name and pedigree now command biotech-scale money before there's a company to diligence. Chai Discovery's $400 million raise at $3.8 billion, coming from actual model output over two years, sets an odd benchmark next to a founder still in talks.
For researchers weighing whether to leave a lab like OpenAI, the math is getting hard to ignore, especially if colleagues follow Wang out the door, as reportedly expected here. For founders in drug discovery, the bar for what counts as fundable is shifting toward reputation and momentum rather than demonstrated wet-lab validation. Investors are clearly betting AI can compress discovery timelines, but that bet is being placed on promise, not proof, at valuations that assume the breakthroughs arrive on schedule.
Worth tracking whether the funding closes at these numbers and, more importantly, what Wang's team actually builds once the checks clear.
Related Reading
Browse all OpenAI news →
Business & Startups Nordic pilot adds Gemini for Education, NotebookLM to boost AI literacy
Business & Startups Kling launches Video O1, all-in-one model with MVL bridge using transformer
Business & Startups DeepSeek Seeks More Capital Weeks After USD 7B Funding Round
Related Topic OpenAI researcher quits, citing distrust over ad‑driven engagement metrics
LLMs & Generative AI
Related Topic OpenAI launches GPT-Image 1.5 with precise editing for enterprise visuals
LLMs & Generative AI
From Archives Anthropic's New AI Ad Campaign Draws Criticism for 'Creepy' Tactics
From Archives Reflection Signs USD 1 Billion Compute Deal With Nebius
From Archives OpenAI's First Hardware Device Is a Movable, Screenless Speaker
Open Source
From Archives OpenAI Targets 2027 for First Major Hardware: A ChatGPT Speaker
LLMs & Generative AI
Common Questions Answered
What is Miles Wang's research background at OpenAI before starting his drug discovery startup?
Miles Wang's research at OpenAI focused on using AI models to speed up scientific and biological work. His expertise in applying AI to accelerated research processes directly informed his decision to launch a company dedicated to AI-driven drug discovery.
What funding round is Miles Wang's AI drug discovery startup targeting?
Miles Wang is reportedly in talks to raise approximately $200 million at a $2 billion valuation for his new drug discovery venture. Lightspeed is said to be discussing a lead position in this funding round, though nothing has been officially signed yet.
How does the startup's focus on repurposing existing drugs provide a competitive advantage?
Wang's startup may develop AI models to identify new uses for existing FDA-approved drugs and those that previously failed in trials. This approach offers significantly faster time to revenue compared to developing entirely new drugs from scratch, since these medicines have already undergone safety testing.
Are other OpenAI researchers expected to join Miles Wang's new venture?
Yes, several OpenAI researchers are expected to follow Miles Wang to his new AI drug discovery startup. This team migration reflects confidence in Wang's vision and expertise in applying AI to biological research challenges.
Why is the valuation significant despite the startup not yet having shipped a product?
The $2 billion valuation demonstrates what is referred to as the 'OpenAI premium,' where a researcher's name, reputation, and pedigree from OpenAI can command substantial biotech-scale funding before the company has launched or produced tangible results. This reflects investor confidence in top-tier AI researcher credentials in the emerging AI drug discovery space.
Further Reading
- OpenAI and Thrive Capital Invest $30M in AI Drug Discovery Startup Chai Discovery - The Entrepreneur Story
- AI is disrupting drug discovery faster than expected - Yahoo Finance
- OpenAI launches early drug discovery AI model GPT-Rosalind - EMJ Reviews
- Reigniting the Discovery Engine for Tomorrow's Cures - OpenAI
